HYDROXYSTILBAMIDINE ISETHIONATE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Dec 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Hydroxystilbamidine isethionate is a small-molecule antimicrobial injectable approved in 1953 for parasitic infections. Mechanism of action and specific indications are not fully documented in available data. This legacy product represents early pharmaceutical antimicrobial development.
LOE Approaching
Mature legacy product with minimal linked positions and low competitive intensity (30%), indicating limited commercial infrastructure and shrinking team size.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job positions indicate this product lacks active career recruitment. Working on a legacy LOE-approaching injectable offers limited advancement and visibility compared to growth-stage assets. Career trajectory here is likely declining with consolidation toward core franchise players.
Medical Affairs SpecialistClinical Liaison
Worked on HYDROXYSTILBAMIDINE ISETHIONATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.